Securities Fraud Investigation Into Ichor Holdings, Ltd. (ICHR) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Ichor Holdings, Ltd. ('Ichor' or the 'Company') (NASDAQ: ICHR) investors concerning the Company's possible violations of the federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ICHOR HOLDINGS, LTD. (ICHR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.
What Happened?
On May 5, 2025, Ichor released its first quarter 2025 financial results, missing EPS and revenue consensus estimates and reporting gross margin of 12.4%, below the forecasted midpoint of 14.5%. The Company explained, 'In Q1, our strategy did not materialize into the margin flow through we anticipated, essentially because we ended up purchasing far more external supply than we had forecasted.'
On this news, Ichor's stock price fell $4.84, or 23.2%, to close at $16.00 per share on May 6, 2025, thereby injuring investors.
Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: shareholders@glancylaw.com
Telephone: 310-201-9150 (Toll-Free: 888-773-9224)
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.
Whistleblower Notice
Persons with non-public information regarding Ichor should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.
About Glancy Prongay & Murray LLP
Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements.
With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Faraday Future Holds First Annual Stockholders' Day, Company Provides FX Product Updates, Confirms FX Super One Launch Timing, and Secures 600 New Deposits from Multi-Channel Network (MCN) Agencies
LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) ('Faraday Future', 'FF' or 'Company'), a California-based global shared intelligent electric mobility ecosystem company, held its first Annual Stockholders' Day on Saturday, May 31, at the Company's global headquarters in Los Angeles. Attendees included stockholders and other Company guests who experienced Company presentations and updates, and personalized FF and FX vehicle ride and drive experiences. The event also offered an open Q&A session with FF executives and a special private dinner after the event for stockholders, offering an exclusive opportunity to engage directly with Company leadership. Words of encouragement from some of the Company's newest B2B partners were also delivered at the event. 'I want to personally thank all of the guests for being here at our very first 'Annual Stockholders' Day. It was a genuine pleasure to extend a welcoming hand to everyone who attended this event,' said Co-CEO YT Jia. 'This was more than just another Company event, it showed our unwavering commitment to stockholder engagement, long-term value creation, and full commitment to our 'Stockholders-First' principle.' FX Product and Brand Updates The Company plans to host the first exclusive offline product launch event for the FX Super One on June 29, tailored for five key groups: FF stockholders and investors; B2B sales partners and prospects; global supply chain partners; media, influencers and KOLs; co-creation officers and celebrities. Subsequently, FX will host a large-scale public launch event on July 17, the 'Super One Online Global Product Launch,' targeting retail consumers and opening up the large-scale online B2C paid pre-orders. FX Super One has now officially entered the parts procurement and production preparation phase. Internally, we've already started the countdown sprint toward having our first production vehicle off-line by year-end. Development of our second model and future products is also progressing steadily and according to plan. The Company is seeing strong momentum with B2B pre-orders for the FX brand. With the latest paid pre-order agreements, totaling 600 units, signed with two MCN agencies: CreatoRev and Good Deal, total binding B2B deposits for FX Super One now cover over 2,500 non-binding pre-orders. This marks significant progress toward FX's goal to disrupt the market dominance of some leading market players such as the Cadillac Escalade. CreatoRev and Good Deal will also collaborate as paid co-creation partners, enhancing the AI-MPV experience. This deep co-creation with leading American MCNs marks a breakthrough and key innovation in FX's Co-Creation Ecosystem Online Direct Sales. Through this, we broke away from influencer advertising and pioneered an end-to-end B2B2C co-creation ecosystem model between an automaker and MCN-affiliated creators, a model that's never been seen before in the global auto industry. At this point, FX's B2B pre-orders now expand to three major categories: FF Par (Partner) program; commercial rental and livery companies; and livestream ecommerce MCN agencies. In the first phase, we are planning to expand our reach across eight U.S. states (California, New York, Florida, Texas, Washington, New Jersey, Neveda, and Massachusetts). FX is expecting to unveil the FX 4 product plan in Q3 2025 and begin accepting pre-orders before year end. Positioned as 'the disruptor of RAV4 in the AIEV era,' the FX 4 is the planned model with the greatest potential to become a true blockbuster and unlock the mainstream market within FX's current product lineup. Company Operation Updates On the user operations front, the Company is accelerating the digitalization, systemization, and IT integration of its user engagement ecosystem, a key accomplishment for the mass production and delivery of FX next year. On the after-sales service front, the Company is advancing the FX Service Par program, working to quickly establish collaborations with major automotive service providers, dealerships, and aftermarket partners. The Company is building a robust internal R&D system, especially centered on bringing much of the software and AI, bringing the core technologies, software, and AI capabilities in our $300,000 flagship FF 91 to the FX product line. In the second half of the year, our voice interaction system based on large language models and the full FF ecosystem of services could be deployed in the planned FX Super One and FX 4. The Company is working to complete the full-vehicle engineering, supply chain integration, testing and validation, mass production readiness, and U.S. regulatory compliance for the Super One and launching the hardware development of the FX 4. FF has successfully built a complete cycle for the FF 91—from product definition to after-sales support. Leveraging our 'Light, Swift, and Empowering' model, FX is able to complete this entire process in less time than the industry average. Middle East Updates As part of FF's global strategy, the Company's Middle East facility in Ras Al Khaimah Economic Zone (RAKEZ) is now ready for occupancy. The local team will be taking over shortly, bringing international production capacity another step closer to reality. In the second half of the year, and contingent on available funding, FX aims to begin production of the FX Super One in the Middle East. The Middle East strategy presents four key values: Faster and more streamlined compliance processes; A high concentration of high net-worth users with strong demand for luxury business-class vehicles like the Super One; A critical opportunity to train our teams and validate our operational systems in preparation for large-scale U.S. market execution; and Visibility from FX's production, sales, and delivery, which will demonstrate our value and could bring strategic investors to the region. ABOUT FARADAY FUTURE Faraday Future is a California-based global shared intelligent electric mobility ecosystem company. Founded in 2014, the Company's mission is to disrupt the automotive industry by creating a user-centric, technology-first, and smart driving experience. Faraday Future's flagship model, the FF91, exemplifies its vision for luxury, innovation, and performance. The new FX strategy aims to introduce mass production models equipped with state-of-the-art luxury technology similar to the FF 91, targeting a broader market with middle-to-low price range offerings. FF is committed to redefining mobility through AI innovation. Join us in shaping the future of intelligent transportation. For more information, please visit FORWARD LOOKING STATEMENTS This press release includes 'forward looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words 'plan to,' 'can,' 'will,' 'should,' 'future,' 'potential,' and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements, which include statements regarding future partnerships, joint ventures and fundraising, plans and projections for the FX brand, including by not limited to the planned Super One and FX 4, future FX models, future FX reservations, use of capital and 10b5-1 purchase plans, are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, among others: the ability to convert pre-orders into sales, none of which are binding; market demand for MPVs and MPV rentals; the Company's ability to secure the necessary funding to execute on its AI, EREV and Faraday X (FX) strategies, each of which will be substantial; the Company's ability to design and develop EREV technology; the Company's ability to design and develop AI-based solutions; competition in the AI and EREV areas, where actual or potential competitors have or are likely to have substantial advantages relative to the Company, including but not limited to experience, expertise, funding, infrastructure and personnel; the ability of the Company to execute across multiple concurrent strategies, including the UAE, bridge strategy, or FX, EREV, AI, and US geographic expansion; the Company's ability to secure necessary agreements to license third-party range extender technology and/or license or produce FX vehicles in the U.S., the Middle East, or elsewhere, none of which have been secured; the Company's ability to homologate FX vehicles for sale in the U.S., the Middle East, or elsewhere; and the Company's ability to secure necessary permits at its Hanford, CA production facility; the potential impact of tariff policy; each executive's ability to cancel or amend his 10b5-1 purchase plan; potential volume limitations under Rule 144 or Rule 145 of the Securities Act of 1933, as amended, or Regulation M; the possible suspension of purchases due to a trading suspension, legal, regulatory or contractual restrictions; a subsequent determination that a 10b5-1 plan does not comply with Rule 10b5-1 or other applicable securities laws; the Company's ability to continue as a going concern and improve its liquidity and financial position; the Company's ability to pay its outstanding obligations; the Company's ability to remediate its material weaknesses in internal control over financial reporting and the risks related to the restatement of previously issued consolidated financial statements; the Company's limited operating history and the significant barriers to growth it faces; the Company's history of losses and expectation of continued losses; the success of the Company's payroll expense reduction plan; the Company's ability to execute on its plans to develop and market its vehicles and the timing of these development programs; the Company's estimates of the size of the markets for its vehicles and cost to bring those vehicles to market; the rate and degree of market acceptance of the Company's vehicles; the Company's ability to cover future warranty claims; the success of other competing manufacturers; the performance and security of the Company's vehicles; current and potential litigation involving the Company; the Company's ability to receive funds from, satisfy the conditions precedent of and close on the various financings described elsewhere by the Company; the result of future financing efforts, the failure of any of which could result in the Company seeking protection under the Bankruptcy Code; the Company's indebtedness; the Company's ability to use its 'at-the-market' program; insurance coverage; general economic and market conditions impacting demand for the Company's products; potential negative impacts of a reverse stock split; potential cost, headcount and salary reduction actions may not be sufficient or may not achieve their expected results; circumstances outside of the Company's control, such as natural disasters, climate change, health epidemics and pandemics, terrorist attacks, and civil unrest; risks related to the Company's operations in China; the success of the Company's remedial measures taken in response to the Special Committee findings; the Company's dependence on its suppliers and contract manufacturer; the Company's ability to develop and protect its technologies; the Company's ability to protect against cybersecurity risks; and the ability of the Company to attract and retain employees, any adverse developments in existing legal proceedings or the initiation of new legal proceedings, and volatility of the Company's stock price. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of the Company's Form 10-K filed with the SEC on March 31, 2025, and other documents filed by the Company from time to time with the SEC.
Yahoo
an hour ago
- Yahoo
HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study — — Webcast to be held at 8:30 am HKT on Tuesday, June 3 to discuss the data presented — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ('HUTCHMED') (Nasdaq/AIM:HCM; HKEX:13) announces primary results from the interim analysis of the SACHI Phase III study. These results were presented in a late-breaking oral presentation on Sunday, June 1, 2025, during the American Society of Clinical Oncology ('ASCO') Annual Meeting in Chicago, USA. SACHI is a Phase III study of the savolitinib and osimertinib combination for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor ('EGFR') mutation-positive non-small cell lung cancer ('NSCLC') with MET amplification after disease progression on first-line EGFR inhibitor therapy ( identifier NCT05015608). Title: Savolitinib combined with osimertinib versus chemotherapy in EGFR-mutant and MET-amplification advanced NSCLC after disease progression on EGFR tyrosine kinase inhibitor: Results from a randomized Phase III SACHI study Lead Author: Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Session: Oral Abstract Session: Lung Cancer - Non-Small Cell Metastatic Abstract Number: LBA8505 Date & Time: Sunday, June 1, 2025, 8:00 AM Central Daylight Time Location: Arie Crown Theater Prof. Shun Lu, Chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University, and Principal Investigator of the SACHI study, said, 'The results from the SACHI Phase III study represent a significant advancement in the treatment of EGFR mutation-positive NSCLC with MET amplification. The savolitinib and osimertinib combination demonstrates promising efficacy in patients who have progressed on prior EGFR inhibitor therapy. These findings highlight the potential of this novel, chemotherapy-free combination to enable a continued oral regimen, offering a convenient and well-tolerated treatment option that addresses critical unmet needs for patients with this challenging disease.' The event will be held in English and can be accessed via A replay will also be available on the website shortly after the event. As of the interim analysis data cut-off of August 30, 2024, a total of 211 patients were randomized to receive the savolitinib and osimertinib combination or chemotherapy. In the intention to treat (ITT) population, the median progression-free survival ('PFS') assessed by investigator was 8.2 months with savolitinib plus osimertinib, compared to 4.5 months with chemotherapy (hazard ratio ['HR'] 0.34; 95% confidence interval ['CI'] 0.23-0.49; p < 0.0001). The independent review committee ('IRC') assessed median PFS was 7.2 months vs 4.2 months, respectively (HR 0.40; 95% CI 0.28-0.59; p < 0.0001). The investigator-assessed objective response rate (ORR) was 58% in the savolitinib plus osimertinib group compared to 34% for patients in the chemotherapy group. The disease control rate (DCR) was 89% vs 67% and the median duration of response (DoR) was 8.4 months vs 3.2 months, respectively. Overall survival was not mature at the time of the interim analysis. Efficacy outcomes in the third-generation EGFR tyrosine kinase inhibitor ('TKI')–treated patients were comparable with those in the intention-to-treat and third-generation EGFR-TKI–naïve populations. In the third generation EGFR-TKI–treated subgroup, the investigator-assessed and IRC-assessed median PFS were highly consistent, both at 6.9 vs 3.0 months (HR 0.32; p < 0.0001). The safety profile of the savolitinib and osimertinib combination was tolerable and no new safety signals were observed. Treatment-emergent adverse events of Grade 3 or above occurred in 57% of patients in the savolitinib plus osimertinib group compared to 57% for patients in the chemotherapy group, suggesting a favorable safety profile. In January 2025, the Independent Data Monitoring Committee (IDMC) of SACHI has considered that the study has met the pre-defined primary endpoint of PFS in a planned interim analysis and as a result, enrollment into the study has concluded. Supported by data from SACHI, a New Drug Application (NDA) for the combination of savolitinib and osimertinib for the treatment of patients with locally advanced or metastatic EGFR mutation-positive NSCLC with MET amplification after disease progression on first-line EGFR inhibitor therapy has been accepted and granted priority review by the China National Medical Products Administration (NMPA). About Savolitinib Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. MET is a tyrosine kinase receptor that has an essential role in normal cell development. Savolitinib blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. MET overexpression and/or amplification can lead to tumor growth and the metastatic progression of cancer cells, and is a known mechanism of acquired resistance to EGFR TKIs. The prevalence of MET depends on the sample type, detection method and assay cut-off used. Savolitinib is approved in China and is marketed under the brand name ORPATHYS® by our partner, AstraZeneca, for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. It has been included in the National Reimbursement Drug List of China (NRDL) since March 2023. It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers as a single treatment and in combination with other medicines. About HUTCHMED HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: or follow us on press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED's current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of savolitinib, the further clinical development for savolitinib, its expectations as to whether any studies on savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. CONTACTS Investor Enquiries +852 2121 8200 / ir@ Media Enquiries FTI Consulting – +44 20 3727 1030 / HUTCHMED@ Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@ Panmure Liberum Nominated Advisor and Joint Broker Atholl Tweedie / Freddy Crossley / Rupert Dearden +44 20 7886 2500 HSBC Joint Broker Simon Alexander / Alina Vaskina / Arnav Kapoor +44 20 7991 8888 Cavendish Joint Broker Geoff Nash / Nigel Birks +44 20 7220 0500
Business Insider
2 hours ago
- Business Insider
DLTR, FIVE, or WMT: Which Retail Stock Is the Best Pick?
Retailers have been under pressure due to the impact of macro uncertainty on consumers' discretionary spending and tariff woes. Nonetheless, Wall Street is bullish on some retail stocks due to their ability to thrive despite short-term challenges. Using TipRanks' Stock Comparison Tool, we placed Dollar Tree (DLTR), Five Below (FIVE), and Walmart (WMT) against each other to find the best retail stock, according to Wall Street analysts. Confident Investing Starts Here: Dollar Tree (NASDAQ:DLTR) Dollar Tree stock has risen 20.4% year-to-date, driven by the discount store chain's efforts to improve its business and the sale of the Family Dollar business that weighed on the company's overall performance in recent years. Investors are also optimistic about Dollar Tree's strategic initiatives, including its multi-price point strategy. The retailer finished Fiscal 2024 with approximately 2,900 3.0 multi-price format stores, and is targeting 5,200 3.0 format stores by the end of 2025. Dollar Tree is scheduled to announce its results for the first quarter of Fiscal 2025 on June 4. Wall Street expects the company to report a 15.4% decline in EPS (earnings per share) to $1.21, while revenue is estimated to fall by more than 40% to $4.54 billion. These estimates reflect the impact of the sale of the Family Dollar business, weakness in consumer spending on discretionary items, and tariff-related pressures. What Is the Target Price for DLTR Stock? Heading into the Q1 FY25 results, Telsey analyst Joseph Feldman increased the price target for Dollar Tree stock to $95 from $82 and reiterated a Hold rating on the stock. The analyst stated that he is maintaining his Q1 2025 and 2025 estimates, thanks to DLTR's increased focus on productivity and profitability due to improving value, convenience, and discovery at its stores. He also expects the retailer to gain from its strategic initiatives, including plans to open about 400 new stores in 2025, expand its multi-price point assortment, and refresh its merchandise. While Feldman highlighted Dollar Tree's strong balance sheet and potential share repurchases, he believes tariff risk remains elevated in H2 2025 and 2026, given that the company directly imports about 40% of its total retail value purchases, mainly from China. Although the company plans to manage and mitigate a large part of tariffs, Feldman believes that overall exposure to imports is high, and the uncertainty related to changes in government policies remains a risk. Wall Street has a Moderate Buy consensus rating on Dollar Tree stock based on six Buys, 11 Holds, and one Sell recommendation. The average DLTR stock price target of $85.29 implies a downside risk of about 5.5% from current levels. Five Below (NASDAQ:FIVE) Five Below is a value retailer that targets teens and pre-teens with merchandise that is mostly priced between $1 and $5, with some items priced beyond $5. FIVE stock has risen 11% so far in 2025, driven by a favorable update on Q1 FY25 results. Also, the temporary agreement between the U.S. and China to slash tariffs also improved investor sentiment. The company is scheduled to announce its Q1 FY25 earnings on June 4. In early May, Five Below raised its Q1 FY25 guidance, with net sales expected to come in at about $967 million compared to the prior guidance of $905 million to $925 million, and comparable sales estimated to rise about 6.7% compared to the prior guidance of about flat to 2% increase. Further, Five Below expects Q1 FY25 adjusted EPS in the range of $0.82 to $0.84, up from the prior outlook of $0.50 to $0.61. Meanwhile, Wall Street expects Five Below to report EPS of $0.78, reflecting a 30% year-over-year growth. Revenue is expected to grow 18.5% to $961.25 million. Is Five Below a Good Stock to Invest? Following the Q1 update, Citi analyst Paul Lejuez increased the price target for Five Below stock to $121 from $80 and reaffirmed a Hold rating. The 5-star analyst noted that the company's revised Q1 FY25 comps guidance was well ahead of the previous outlook. Lejuez added that with comparisons easing significantly in Q2 FY25, he sees the possibility of Five Below delivering double-digit comparable sales growth, driven by its efforts to improve its assortment and simplify the pricing strategy. Further, the analyst expects Five Below to maintain its Fiscal 2025 outlook despite tariffs. With six Buys, 13 Holds, and one Sell recommendation, Wall Street has a Hold consensus rating on Five Below stock. The average FIVE stock price target of $98.53 implies about 15.6% upside potential from current levels. FIVE stock has advanced 11% so far in 2025. Walmart (NYSE:WMT) Big-box retailer Walmart delivered better-than-expected earnings for the first quarter of Fiscal 2026, though sales slightly lagged expectations. The company attributed its performance to higher transaction counts and unit volumes, along with robust e-commerce growth. While Walmart is not immune to tariffs, it is considered more resilient compared to its rivals due to its greater exposure to groceries and essentials compared to rivals who sell more discretionary goods. Moreover, the retailer is able to attract customers with its lower prices. Walmart is also strengthening customer engagement with faster deliveries, store remodels, and a wider assortment of brands. Is Walmart Stock a Buy, Hold, or Sell? In reaction to the Q1 FY26 print, Raymond James analyst Bobby Griffin reiterated a Buy rating on Walmart stock with a price target of $105. The 5-star analyst noted that Walmart exceeded Q1 estimates and reaffirmed its FY26 guidance despite heightened macro and tariff-related uncertainty. Griffin believes that Walmart is uniquely positioned to navigate the ongoing challenges, thanks to its diversified sourcing, replenishable assortment, disciplined inventory planning, and a structurally advantaged model across e-commerce and supply chain. He added that Walmart continues to lean into high-margin revenue streams, with advertising, membership, and marketplace all delivering strong growth and expanding contribution to profit. Griffin highlighted that Walmart's e-commerce business turned profitable in the U.S. and globally for the first time, a key milestone that supports long-term EBIT margin expansion. Over the long term, Griffin continues to view Walmart as a well-positioned retailer that can grow its operating income faster than sales, as the profit mix shifts further toward digital, data, and automation-enabled initiatives. Overall, Walmart scores a Strong Buy consensus rating based on 28 Buys and two Holds. The average WMT stock price target of $109.38 implies about 11% upside potential from current levels. WMT stock has risen 9.3% year-to-date. Conclusion Wall Street is highly bullish on Walmart, cautiously optimistic on Dollar Tree, and sidelined on Five Below stock. Currently, analysts see downside risk in Five Below and Dollar Tree stocks, while they expect further upside in WMT stock. Walmart's value proposition, robust e-commerce growth, and huge scale are some of the strengths that support analysts' bullish thesis.
